Health

What's the real extent of industry payments to doctors?

More than three in every five Americans see a doctor who receives some form of payment from industry. This is according to a new survey led by Genevieve Pham-Kanter of Drexel University's Dornsife School of Public Health ...

Medications

Bronchial carcinoma: Added benefit of crizotinib not proven

Since August 2016 crizotinib (trade name: Xalkori) has also been available for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme "proto-oncogene tyrosine-protein kinase" (ROS1) is ...

Medications

Outcomes-based pricing suggested for new, costly drugs

(HealthDay)—Outcomes-based pricing for novel and expensive biopharmaceuticals is supported in an Ideas and Opinions piece published online Dec. 13 in the Annals of Internal Medicine.

Diseases, Conditions, Syndromes

Public skepticism would likely greet a new Zika vaccine, study says

As scientists race to create a vaccine for the Zika virus, new research from the University of Georgia suggests almost half of Americans wouldn't be interested in getting the shot even if public health officials recommended ...

Medications

Crizotinib in bronchial carcinoma: New data not informative

Crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) with high activity of the enzyme anaplastic lymphoma kinase (ALK) who have already ...

Medications

Brivaracetam in epilepsy: Added benefit still not proven

Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adults and adolescents from 16 years of age with epileptic seizures. The German Institute for Quality and Efficiency in Health ...

page 25 from 40